Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus carboplatin and pemetrexed versus carboplatin and pemetrexed for EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
CTR20202633Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amivantamab, carboplatin, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Mar 2021; status: active.
02
Drugs
amivantamabcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202633.